WuXi AppTec acquires preclinical CRO

By Melissa Fassbender

- Last updated on GMT

iStock/Sean_Kuma
iStock/Sean_Kuma

Related tags: Corporation, Subsidiary

WuXi AppTec has acquired Shanghai-based HD Biosciences (HDB), a biology-focused preclinical contract research organization (CRO). 

HD Biosciences, which also has facilities in Beijing and the US, will become a wholly-owned subsidiary of WuXi.

According to WuXi AppTec, the acquisition will strengthen the company’s research and development capabilities from target validation to lead discovery and optimization.

HD Biosciences’ capabilities include plate-based pharmacology and screening as well as AGMTM based target validation.

In a press statement, Dr. Xuehai Tan, Chairman and CEO of HD Biosciences, said the integration of services will enable the company to meet its growing customer needs.

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related products

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us

Products

View more

Webinars